We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Filana Therapeutics, Inc.는 임상 단계 생명공학 기업으로, 신경퇴행성 질환 치료제를 개발하고 있습니다. 주요 치료제 후보 물질은 알츠하이머병 치료를 위해 3상 임상 시험 중인 저분자 화합물 simufilam입니다. 또한, 진단용 후보 물질인 SavaDx는 소량의 혈액 샘플로 알츠하이머병 발병 여부를 감지하는 데 초점을 맞춘 초기 단계 프로그램입니다. 이 회사는 과거 Cassava Sciences, Inc.로 알려졌으며, 2026년 3월 Filana Therapeutics, Inc.로 사명을 변경했습니다. 1998년에 설립되었으며, 텍사스주 오스틴에 본사를 두고 있습니다.